I-DXd plus atezolizumab for first-line extensive SCLC
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new combination of drugs (I-DXd and atezolizumab, with or without carboplatin) as your first treatment for extensive stage small cell lung cancer. It has two groups: one for people who haven't started treatment yet, and another for those who've already had 4 cycles of a standard chemo-immunotherapy combination and are stable or better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have extensive stage small cell lung cancer (cancer that has spread beyond one lung).
- You cannot have had prior treatment with certain targeted drugs (like orlotamab or enoblituzumab).
- You must be willing to have tumor biopsies if you haven't started treatment yet (Cohort 2).
- You need to be in good physical shape (able to do daily activities, not bedridden).
- If you have brain metastases, they must be treated and stable, not causing symptoms.
- You must not have had an autoimmune disease or serious lung inflammation before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two immunotherapy drugs (sintilimab and tafolecimab) plus standard chemotherapy as a first treatment for extensive-stage small cell lung cancer. The goal is to see if adding these drugs helps people live longer and have better outcomes.
This study tests a combination of an immunotherapy drug (tislelizumab) plus chemotherapy followed by targeted chest radiation as the first treatment for extensive-stage small cell lung cancer. The goal is to see if adding radiation after chemo-immunotherapy works better than standard treatment alone.
This trial tests a combination of two immunotherapy drugs (ivonescimab and cadonilimab) plus chemotherapy for people with extensive-stage small cell lung cancer. It's for those who either haven't been treated before or have had only one prior treatment that included a PD-1/PD-L1 drug and it worked for a while.
This trial tests a combination of an immunotherapy drug (tislelizumab), chemotherapy, and then radiation to the chest for people with extensive-stage small cell lung cancer who haven't had prior treatment. The goal is to see if this approach helps control the cancer longer.
This trial tests whether adding the immunotherapy drug atezolizumab to standard chemotherapy helps people with extensive-stage small cell lung cancer. It is for those who have not had treatment for this stage yet.
This trial tests a new study medicine, PF-08634404, combined with chemotherapy for people with extensive-stage small cell lung cancer. It aims to see if this combination works better than standard treatments.
Hear when a new Small Cell Lung Cancer Extensive Stage trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.